TOP TEN perturbations for 38740_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38740_at
Selected probe(set): 211962_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38740_at (211962_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
PMA study 2 / mock treated MONO-MAC-6 cell sample
Relative Expression (log2-ratio):7.234743Number of Samples:3 / 2
Experimental | PMA study 2 |
MONO-MAC-6 (MM6) cells were treated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:--- | |
Control | mock treated MONO-MAC-6 cell sample |
MONO-MAC-6 (MM6) cells mock treated. |
LPS study 4 / mock treated MONO-MAC-6 cell sample
Relative Expression (log2-ratio):6.567232Number of Samples:2 / 2
Experimental | LPS study 4 |
MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
Control | mock treated MONO-MAC-6 cell sample |
MONO-MAC-6 (MM6) cells mock treated. |
PMA study 2 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample
Relative Expression (log2-ratio):6.474964Number of Samples:3 / 2
Experimental | PMA study 2 (shRNA contr.) |
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:--- | |
Control | mock treated / transduced MONO-MAC-6 cell sample |
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated. |
LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample
Relative Expression (log2-ratio):5.6622496Number of Samples:2 / 2
Experimental | LPS study 4 (shRNA contr.) |
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
Control | mock treated / transduced MONO-MAC-6 cell sample |
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated. |
PMA study 2 (shRNA cycT1) / cycT1 depletion study 2 (shRNA)
Relative Expression (log2-ratio):5.303565Number of Samples:3 / 2
Experimental | PMA study 2 (shRNA cycT1) |
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:--- | |
Control | cycT1 depletion study 2 (shRNA) |
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated. |
LPS study 4 (shRNA cycT1) / cycT1 depletion study 2 (shRNA)
Relative Expression (log2-ratio):4.273983Number of Samples:2 / 2
Experimental | LPS study 4 (shRNA cycT1) |
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
Control | cycT1 depletion study 2 (shRNA) |
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated. |
PMA study 3 (shRNA contr.) / mock treated / transduced Jurkat cell sample
Relative Expression (log2-ratio):3.7555199Number of Samples:2 / 2
Experimental | PMA study 3 (shRNA contr.) |
Jurkat cells were transduced with a control shRNA and then treated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:--- | |
Control | mock treated / transduced Jurkat cell sample |
Jurkat cells were transduced with a control shRNA and then mock treated. |
PMA study 3 (shRNA cycT1) / cycT1 depletion study 1 (shRNA)
Relative Expression (log2-ratio):3.4390125Number of Samples:2 / 2
Experimental | PMA study 3 (shRNA cycT1) |
Jurkat cells were transduced with shRNA against cyclin T1 and then treated with 10ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:--- | |
Control | cycT1 depletion study 1 (shRNA) |
Jurkat cells were transduced with shRNA against cyclin T1 and then mock treated. |
glioma study 27 (glioblastoma, NOS) / glioma study 27 (pilocytic astrocytoma)
Relative Expression (log2-ratio):3.273305Number of Samples:4 / 2
Experimental | glioma study 27 (glioblastoma, NOS) |
Primary tumor samples from resected brain tissues of patients with glioblastoma, NOS(WHO grade IV astrocytoma). | |
Control | glioma study 27 (pilocytic astrocytoma) |
Primary tumor samples from resected brain tissues of patients with pilocytic astrocytoma (WHO grade I astrocytoma). |
stem cell differentiation study 59 (iDRG; 12d) / stem cell differentiation study 59 (8d)
Relative Expression (log2-ratio):-3.2615175Number of Samples:4 / 4
Experimental | stem cell differentiation study 59 (iDRG; 12d) |
Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 4 days. Further details are described in the paper. | |
Control | stem cell differentiation study 59 (8d) |
WA09 embryonic stem cell samples differentiated for 8 days. Further details are described in the paper. |